Version 1
: Received: 4 September 2024 / Approved: 5 September 2024 / Online: 5 September 2024 (12:28:41 CEST)
How to cite:
Benedyk-Machaczka, M.; Mydel, P.; Mäder, K.; Kaminska, M.; Taudte, N.; Naumann, M.; Kleinschmidt, M.; Sarembe, S.; Kiesow, A.; Eick, S.; Buchholz, M. Preclinical Validation of MIN-T: A Novel Controlled-Released Formulation for the Adjunctive Local Application of Minocycline in Periodontitis. Preprints2024, 2024090433. https://doi.org/10.20944/preprints202409.0433.v1
Benedyk-Machaczka, M.; Mydel, P.; Mäder, K.; Kaminska, M.; Taudte, N.; Naumann, M.; Kleinschmidt, M.; Sarembe, S.; Kiesow, A.; Eick, S.; Buchholz, M. Preclinical Validation of MIN-T: A Novel Controlled-Released Formulation for the Adjunctive Local Application of Minocycline in Periodontitis. Preprints 2024, 2024090433. https://doi.org/10.20944/preprints202409.0433.v1
Benedyk-Machaczka, M.; Mydel, P.; Mäder, K.; Kaminska, M.; Taudte, N.; Naumann, M.; Kleinschmidt, M.; Sarembe, S.; Kiesow, A.; Eick, S.; Buchholz, M. Preclinical Validation of MIN-T: A Novel Controlled-Released Formulation for the Adjunctive Local Application of Minocycline in Periodontitis. Preprints2024, 2024090433. https://doi.org/10.20944/preprints202409.0433.v1
APA Style
Benedyk-Machaczka, M., Mydel, P., Mäder, K., Kaminska, M., Taudte, N., Naumann, M., Kleinschmidt, M., Sarembe, S., Kiesow, A., Eick, S., & Buchholz, M. (2024). Preclinical Validation of MIN-T: A Novel Controlled-Released Formulation for the Adjunctive Local Application of Minocycline in Periodontitis. Preprints. https://doi.org/10.20944/preprints202409.0433.v1
Chicago/Turabian Style
Benedyk-Machaczka, M., Sigrun Eick and Mirko Buchholz. 2024 "Preclinical Validation of MIN-T: A Novel Controlled-Released Formulation for the Adjunctive Local Application of Minocycline in Periodontitis" Preprints. https://doi.org/10.20944/preprints202409.0433.v1
Abstract
Adjunctive treatment of periodontitis lacks solutions allowing enough time for wound healing in the periodontal pockets by avoiding a fast re-colonization. Such a solution might be an antibiotic containing formulation with a controlled release over weeks. Here, a recently described minocycline containing approach is qualified for further clinical development by focusing on proof-of-concept, systemic burden, resistance development and degradation studies. Animal studies were done in two different (mouse-chamber, rat Porphyromonas gingivalis challenging) models, including effects on inflammation markers, bone loss and bone structure. Also, serum concentrations of minocycline after local application were determined by HPLC-MS/MS. The resistance status of bacterial clinical isolates against minocycline was investigated and the degradation of the formulation was characterized by laser scanning- and scanning electron microscopy. Animal studies clearly demonstrated the applicability of the new formulation in the investigated models. Inflammation markers decreased dosage dependent and reduced bone loss compared to non-treated group was observed. Thereby, the systemic burden of the antibiotic was neglectable. Minocycline is still effective against oral pathogens; resistance development was not seen. The biodegradable thread was first swollen and subsequently degraded over weeks. The results support the continued clinical development of this new formulation. A phase I clinical trial is planned to further evaluate its safety and efficacy.
Medicine and Pharmacology, Dentistry and Oral Surgery
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.